Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsMolecular Targeted Therapeutics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1594995

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1594995

Research Antibodies

PUBLISHED:
PAGES: 93 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Research Antibodies Market to Reach US$5.8 Billion by 2030

The global market for Research Antibodies estimated at US$4.2 Billion in the year 2023, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Reagent, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Antibodies segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 4.6% CAGR

The Research Antibodies market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Research Antibodies Market - Key Trends & Drivers Summarized

What Makes Research Antibodies Vital in Scientific Discovery?

Research antibodies are essential tools in biological research, utilized for their ability to precisely bind to specific proteins, allowing scientists to detect, measure, and manipulate biomolecules within complex biological samples. These antibodies play a critical role across various fields, including molecular biology, immunology, oncology, and neuroscience, as they enable researchers to investigate cellular processes, signaling pathways, and disease mechanisms. Antibodies are used in techniques such as Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA), among others, to identify proteins or other antigens in tissues and cells. Their specificity and versatility make research antibodies indispensable for advancing our understanding of fundamental biology and disease pathology.

In the era of precision medicine and personalized therapies, research antibodies have become even more crucial as they allow for targeted analysis at the molecular level. For instance, in cancer research, antibodies are frequently used to detect biomarkers that inform treatment decisions and monitor disease progression. By enabling such detailed molecular profiling, research antibodies support both basic science and clinical applications. With the growing importance of biomarkers in diagnostics and therapeutic decision-making, the demand for high-quality, reliable antibodies is on the rise. This makes research antibodies essential tools not only for advancing scientific knowledge but also for improving patient outcomes through their application in translational and clinical research.

How Are Technological Innovations Shaping the Research Antibodies Market?

Technological advancements have greatly expanded the capabilities and applications of research antibodies, leading to the development of more specific, stable, and reproducible antibodies. One of the major innovations is the development of recombinant antibodies, which are produced using gene cloning and expression techniques. Unlike traditional monoclonal antibodies, recombinant antibodies offer higher consistency and are not subject to batch-to-batch variability, making them more reliable for experimental research. This consistency is particularly valuable in clinical and pharmaceutical applications, where reproducibility is essential for accurate analysis. Additionally, recombinant antibodies can be engineered to have higher specificity and affinity for target antigens, reducing the likelihood of off-target effects and improving the accuracy of experimental results.

Another significant technological advancement is the emergence of single-domain antibodies, or "nanobodies," derived from camelid antibodies. These nanobodies are smaller and more stable than traditional antibodies, making them ideal for applications where traditional antibodies may be too large or unstable, such as in live-cell imaging and intracellular studies. Nanobodies have the potential to access and bind to targets within cells, opening new possibilities for studying protein interactions in real time. Furthermore, automation and high-throughput screening technologies are enabling faster and more efficient antibody development processes, allowing researchers to screen large libraries of antibodies to identify the most effective candidates. These innovations are reshaping the research antibodies market by providing scientists with a wider range of tools tailored to the evolving needs of modern research.

What Challenges and Opportunities Exist in the Research Antibodies Market?

While research antibodies are invaluable to scientific discovery, the market faces significant challenges related to product quality and reproducibility. One of the primary concerns is that not all commercially available antibodies meet the required standards for specificity and consistency. Batch-to-batch variability and inadequate validation are common issues that can lead to unreliable experimental results, ultimately impacting the credibility of research findings. Furthermore, the presence of non-specific binding or cross-reactivity can produce false positives or negatives, complicating data interpretation. Researchers and institutions increasingly call for standardized validation protocols and transparent data on antibody performance to address these issues and ensure reproducibility in scientific research.

However, these challenges have also spurred opportunities for growth and innovation in the market. Companies are now investing in rigorous quality control and validation processes, including independent third-party testing, to assure researchers of the reliability of their products. Additionally, there is an increasing demand for customized antibody solutions tailored to specific research needs. Custom antibody services provide researchers with antibodies that are optimized for their unique targets and applications, often through recombinant techniques. As researchers seek higher standards and customization in antibodies, the market is shifting toward more specialized offerings and enhanced validation. Furthermore, as more academic institutions and research funding bodies emphasize reproducibility, companies that can deliver well-validated and reliable antibodies are poised to gain a competitive advantage.

What Are the Key Drivers Accelerating the Research Antibodies Market?

The growth in the research antibodies market is driven by several factors, reflecting advancements in biomedical research and the rising demand for high-quality research tools. The increasing prevalence of diseases such as cancer, autoimmune disorders, and infectious diseases is one of the primary drivers, as researchers seek antibodies to study disease pathways, identify biomarkers, and develop potential therapeutic targets. In cancer research, for example, antibodies are used extensively to identify specific protein markers that help researchers understand tumor behavior, assess prognosis, and design personalized treatments. The expanding application of antibodies in drug development, where they are used to test drug efficacy and monitor potential off-target effects, is also driving market growth.

Another key driver is the growing investment in research and development by academic institutions, pharmaceutical companies, and government agencies. As the demand for new therapies and diagnostic tools rises, funding for biomedical research has increased, creating a robust market for research antibodies. Additionally, the increasing adoption of high-throughput screening techniques in drug discovery is further boosting the demand for reliable antibodies that can be used in large-scale studies. With advances in fields like genomics and proteomics, there is also a rising need for antibodies that can target a broad range of proteins, enabling detailed molecular analysis. Finally, government policies that support biomedical research, particularly in regions like North America and Europe, have strengthened the market, helping to ensure sustained growth and innovation in the research antibodies sector.

SCOPE OF STUDY:

The report analyzes the Research Antibodies market in terms of US$ Million by the following Application; End-Use; Product; Technology, and Geographic Regions/Countries:

Segments:

Product (Reagent, Antibodies); Technology (Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation, Other Technologies); Application (Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology, Other Applications); End-Use (Pharma & Biotech Companies, Academic & Research Institutions, Contract Research Organizations (CROs))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Abcam plc
  • Active Motif, Inc.
  • Affinity Biologicals, Inc.
  • Agilent Technologies, Inc.
  • BD
  • Beckman Coulter, Inc.
  • Bethyl Laboratories, Inc.
  • Bio SB
  • BioLegend, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • Jackson ImmunoResearch Inc.
  • Lonza
  • Merck KGaA
  • Miltenyi Biotec
  • OriGene Technologies, Inc.
  • PerkinElmer Inc.
  • QIAGEN
  • Rockland Immunochemicals, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Show more
Product Code: MCP22701

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Research Antibodies - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Prevalence of Chronic Diseases and Cancer Drives Demand for Research Antibodies in Diagnostics and Therapeutics
    • Increasing Investment in Biomedical Research Expands Addressable Market for High-quality Research Antibodies
    • Advancements in Recombinant Antibody Technology Enhance Consistency and Reproducibility, Strengthening Demand
    • Rising Focus on Precision Medicine Spurs Need for Specific and Customizable Antibody Solutions
    • Expansion of Proteomics and Genomics Research Drives Adoption of Antibodies for Target Identification and Validation
    • Increased Use of Antibodies in Drug Discovery Pipelines Propels Demand for Functional and High-affinity Antibodies
    • Technological Innovations in Antibody Production Streamline Manufacturing and Accelerate Market Growth
    • Growing Adoption of Antibodies in Diagnostic Assays Expands Market for Disease-specific and Marker-specific Antibodies
    • Rising Demand for Monoclonal and Polyclonal Antibodies in Academic Research Institutions Supports Market Growth
    • Emerging Applications of Antibodies in Neuroscience and Immunology Foster Development of Specialized Antibody Products
    • Increased Collaboration Between Antibody Manufacturers and Pharmaceutical Companies Drives Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Research Antibodies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Research Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Research Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Reagent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Reagent by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Western Blotting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Western Blotting by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Flow Cytometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Flow Cytometry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Immunofluorescence by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Immunofluorescence by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Immunoprecipitation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Immunoprecipitation by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World 7-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World 7-Year Perspective for Stem Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Neurobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: World 7-Year Perspective for Neurobiology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 37: World 7-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World 7-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 40: USA Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 41: USA 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 43: USA 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: USA 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • CANADA
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Canada 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Canada 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Canada 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • JAPAN
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Japan 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Japan 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • CHINA
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 64: China Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 65: China 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 66: China Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 67: China 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 70: China Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 71: China 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • EUROPE
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Research Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 73: Europe 7-Year Perspective for Research Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Europe 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 79: Europe 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • FRANCE
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 82: France Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 83: France 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 84: France Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 85: France 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 88: France Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 89: France 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • GERMANY
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Germany 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Germany 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 96: Germany Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Germany 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 101: Italy 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 103: Italy 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • UNITED KINGDOM
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 106: UK Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 107: UK 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 108: UK Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 109: UK 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 112: UK Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 113: UK 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 131: Rest of World 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 133: Rest of World 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 137: Rest of World 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!